Note: Carousel will only load on frontend.

Our pharma partners in the Milner Therapeutics Consortium have been working together with academics at the University, Babraham and Wellcome Sanger Institutes to better understand disease mechanisms and to discover and validate new therapeutic targets. These pre-clinical projects range from reagent sharing and 6-month pilots to 2-year postdoctoral funded collaborations and are expected to lead to joint publications with the company partners.


The 2024 Consortium Call, which closed on 11th March, sought project proposals to current challenges in:

  • Neuroscience
  • Immunology & Inflammation
  • New technologies that will aid therapeutic discovery
  • Infectious Disease
  • Oncology
  • Reproductive Medicine
  • Metabolic & Cardiovascular disease

We can provide the following items for successful projects:

  • Support for pilot (6 months) or longer-term projects (1-2 years)
  • Funding e.g. for a research associate and consumables
  • Access to company reagents where appropriate e.g. tool compounds, compound libraries
  • Expertise e.g. in particular techniques, disease areas, target selection and validation

If you have any questions, or an idea for a new collaborative project in key research focus areas, email our Consortium Manager, Asha Carpenter: